Name: Australian Clinical Labs (ACL) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ACL

Health Care Equipment & Services

Australian Clinical Labs

Short interest: 4.40%; −0.44 pp 30d; as of 9 Oct 2026
Reported shorts: 8.2M
Shares on issue: 186.519M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Australian Clinical Labs

Australian Clinical Labs is a leading provider of pathology services in Australia, offering a comprehensive range of diagnostic testing services. The company operates over 50 NATA-accredited laboratories and more than 1,200 collection centers, serving a diverse clientele. Its commitment to quality and innovation positions it as a key player in the healthcare sector.

Company profile →

Australian Clinical Labs (ASX:ACL) has 4.40% of its shares on issue reported as short positions as of 9 Oct 2026, or about 8,199,820 shares. Over the past 30 days that figure has fallen 0.44 percentage points, and over 90 days it has fallen 2.41 percentage points. Its highest recorded short interest was 11.19% in July 2024. ACL is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ACL today

Zanger BreakoutWatchScore 34rank 377 of 1893
CAN SLIMWatchScore 23rank 550 of 1549
Minervini Trend TemplateWatchScore 55rank 200 of 1684
Crowded-Short BreakoutWatchScore 37rank 91 of 1448
Quality compoundersWatchScore 22rank 650 of 1660

Prices to 15 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ACL fundamentals

In the year to 30 Jun 2026, Australian Clinical Labs (ASX:ACL) recorded revenue of A$735.8M and net profit after tax of A$23.7M. A year earlier it recorded revenue of A$736.1M and net profit after tax of A$32.4M. Year-on-year growth: revenue −0.1% (FY), EPS −27.7% (TTM). Net margin 3.2% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →